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Abstract
Introduction: Newborns in need of extracorporeal membrane oxygenation (ECMO) support are at high risk of
developing acute kidney injury (AKI). AKI may occur as part of multiple organ failure and can be aggravated by
exposure to components of the extracorporeal circuit. AKI necessitates adjustment of dosage of renally eliminated
drugs and avoidance of nephrotoxic drugs. We aimed to define systematically the incidence and clinical course of
AKI in critically ill neonates receiving ECMO support.
Methods: This study reviewed prospectively collected clinical data (including age, diagnosis, ECMO course, and
serum creatinine (SCr)) of all ECMO-treated neonates within our institution spanning a 14-year period. AKI was
defined by using the Risk, Injury, Failure, Loss of renal function, and End-stage renal disease (RIFLE) classification.
SCr data were reviewed per ECMO day and compared with age-specific SCr reference values. Accordingly, patients
were assigned to RIFLE categories (Risk, Injury, or Failure as 150%, 200%, or 300% of median SCr reference values).
Data are presented as median and interquartile range (IQR) or number and percentage.
Results: Of 242 patients included, 179 (74%) survived. Median age at the start of ECMO was 39 hours (IQR, 26 to
63); median ECMO duration was 5.8 days (IQR, 3.9 to 9.4). In total, 153 (64%) patients had evidence of AKI, with
72 (30%) qualifying as Risk, 55 (23%) as Injury, and 26 (11%) as Failure. At the end of the study period, only
71 (46%) patients of all 153 AKI patients improved by at least one RIFLE category. With regression analysis, it was
found that nitric oxide ventilation (P = 0.04) and younger age at the start of ECMO (P = 0.004) were significant
predictors of AKI. Survival until intensive care unit discharge was significantly lower for patients in the Failure
category (35%) as compared with the Non-AKI (78%), Risk (82%), and Injury category (76%), with all P < 0.001,
whereas no significant differences were found between the three latter RIFLE categories.
Conclusions: Two thirds of neonates receiving ECMO had AKI, with a significantly increased mortality risk for
patients in the Failure category. As AKI during childhood may predispose to chronic kidney disease in adulthood,
long-term monitoring of kidney function after ECMO is warranted.
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Introduction
Extracorporeal membrane oxygenation (ECMO) is an
advanced cardiopulmonary bypass (CPB) technique pro-
viding mechanical life support to critically ill patients
with acute reversible respiratory or cardiovascular fail-
ure, not responding to conventional intensive care.
Many neonatal ECMO candidates already have an
inflammatory response before the start of ECMO because
of asphyxia, hypoxia, infection, or shock. Unfortunately
for these already critically ill patients, exposure to com-
ponents of the ECMO circuit can aggravate this inflam-
matory response, resulting in a so-called capillary leakage
syndrome [1]. High levels of circulating endotoxins, exo-
toxins, interleukins, and leukotrienes from activated
leukocytes and thrombocytes, as well as complement
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factors, bring harm to the capillary basement membranes
[2]. This leads not only to water and small-molecule leak-
age through the capillary membrane, but also to leakage
of relatively large molecules, including albumin, resulting
in generalized edema. The blood pressure will decrease
because of extravasation of water and proteins, necessi-
tating administration of vasopressor drugs. Low blood
pressure and tissue edema may cause deficient tissue per-
fusion and oxygenation, leading to further organ failure,
of which aggravation of existent lung failure and oliguric
kidney failure are most prominent.
Acute kidney injury (AKI) requires adjustment of
treatment in the short-term; for example, dosages of
renally eliminated drugs should be adjusted, and
nephrotoxic drugs must be avoided. Reported incidences
of AKI among critically ill neonates admitted to a pedia-
tric Intensive Care Unit (ICU) vary widely, between
4.5% and 82.0% [3-8]. This large range is partly
explained by the lack of a standard definition of AKI.
For that reason, the Acute Dialysis Quality Initiative
group proposed a classification system for use in criti-
cally ill adult patients, termed the RIFLE criteria [9].
The classification comprises three levels of severity -
Risk, Injury, and Failure - and two outcomes: loss of
renal function and end-stage renal disease. It is based
on changes in serum creatinine (SCr) levels and dura-
tion of oliguria. Subsequently, Akcan-Arikan and collea-
gues [5] proposed a RIFLE classification adapted for
pediatrics (pRIFLE). The RIFLE criteria demonstrated
clinical relevance for diagnosing AKI, classifying its
severity, monitoring the progression of AKI, and pre-
dicting mortality in hospitalized adult and pediatric
patients [7,8,10].
Previous research showed that renal failure is common
both in adults and children receiving ECMO and is
associated with increased mortality [3,6,11-13]. By using
the Extracorporeal Life Support Organization (ELSO)
Registry, Askenazi and colleagues [14] performed a large
cross-sectional study in ECMO-treated neonates and
children. Of the 7,941 neonates studied, 27.4% died. AKI
(SCr >1.5 mg/dl) occurred more often in nonsurvivors
than in survivors (19.0% versus 3.9%; P < 0.0001), and
more nonsurvivors were treated with renal-replacement
therapy (RRT) than were survivors (39.7% versus 16.0%;
P < 0.0001). This and earlier studies in ECMO-treated
patients tend to be limited for several reasons. First, the
used upper limit for the definition of AKI (SCr >1.5 mg/dl)
is debatable, as it does not necessarily indicate kidney
injury. In newborns, this cut-off value may include lower
grades of AKI, whereas in older infants, this definition
corresponds only to severe cases of the RIFLE category,
Failure. Second, information is lacking on the time points
when SCr levels peaked and on allocation of RRT, which
may have prevented patients from ever reaching increased
SCr levels. Therefore, the aim of this study was to define
systematically the incidence and clinical course of AKI in
critically ill neonates receiving ECMO support, by using
SCr concentrations and consequent RIFLE categories in
the time frame before we applied standard continuous
hemofiltration (HF) [15].
As a secondary objective, we aimed to describe the
relation between the severity of AKI and survival until
ICU discharge.
Methods
Setting
The ICU at the Erasmus MC-Sophia Children’s Hospital,
Rotterdam, has been serving as an ECMO facility since
1992. This tertiary hospital is one of the two pediatric
centers providing ECMO support in The Netherlands.
Since 1992, more than 550 children (up to 18 years of
age) have been treated with ECMO, presently at a rate of
30 ECMO runs annually. Two thirds of children receiving
ECMO support are neonates. During the study period,
the venoarterial bypass procedure was the common
initial procedure. ECMO support was considered in
patients with potentially reversible cardiac and/or
respiratory failure unresponsive to optimal conventional
therapy, including nitric oxide- and/or high-frequency
oscillatory ventilation, maximal fluid resuscitation, and
administration of inotropic and vasopressive drugs to
maintain the mean arterial pressure within age-adjusted
reference values.
Entry criteria for ECMO were a prolonged oxygena-
tion index >25; prolonged alveolar-arterial oxygen differ-
ence >600 mm Hg; cardiorespiratory failure for more
than 2 hours with pH <7.15 and PaO2 <5.3 kPa. Contra-
indications for ECMO were gestational age <34 weeks;
<2.0 kilograms; mechanical ventilation for more than 10
days; preexisting intracranial hemorrhage; coagulopathy;
and/or other severe congenital anomalies. During the
study period, these criteria did not change.
Patients
In this cohort study, we reviewed data of all full-term
neonates (≤28 days of age) who received ECMO support
within our institution between January 1992 and January
2006. Patients were not eligible for the study if ECMO
support had been combined with standard continuous
HF for intravascular volume management, which has
been part of the clinical protocol since 2005. In contrast,
patients who received HF secondary to AKI were
enrolled. Other reasons for exclusion were preexisting
structural renal anomalies. If a patient had undergone
more than one ECMO run, only data related to the first
run were included.
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Variables
Data were retrieved from our electronic data registry and
the hospital’s Patient Data Management System (PDMS),
which stores all prospectively collected physiological
parameters, laboratory results, and therapeutic modal-
ities. Demographic variables were retrieved from the
patients’ medical records: age and weight at the start of
ECMO, gender, primary diagnosis leading to the initia-
tion of ECMO, Apgar scores at 1, 5, and 10 minutes after
birth, perinatal asphyxia, cardiac arrest, the use of nitric
oxide (NO) ventilation, and the administration of vaso-
pressor drugs before ECMO. The following data on the
ECMO run were retrieved: type of ECMO (for example,
venoarterial or venovenous) and ECMO course (for
example, ECMO duration, need for major surgery, and
progressive heart failure during ECMO). In addition, we
used length of ICU stay and survival until ICU discharge.
With regard to survival, we distinguished between early
nonsurvivors and late nonsurvivors by using a cut-off
point of 24 hours after ECMO.
AKI definition
SCr was assessed by enzymatic assay (Creatinine Plus;
Roche Diagnostics, Branchburg, NJ, USA) on a Hitachi
912 analyzer, as described elsewhere [16]. SCr was mea-
sured daily as part of standard clinical care. When SCr
was not available on a day of treatment, the absent mea-
surement was reported as a missing value. When more
than one SCr measurement had been performed on a
single day of treatment, the mean of these values was
used. When HF was provided, SCr measurements were
disregarded.
To determine the clinical course and severity of AKI,
patients were assigned SCr-based RIFLE scores on each
day of ECMO treatment: R (risk for kidney injury), I
(injury to the kidney), and F (failure of kidney function)
[9]. RIFLE strata L (loss of renal function) and E (end-
stage renal disease) were not scored, as the study period
was restricted to the first 12 days of ECMO treatment.
Because, in many cases, no pre-ECMO SCr concentra-
tions were available, RIFLE categories Risk, Injury, and
Failure were defined as, respectively, SCr above 150%,
200%, and 300%, of the median of locally collected SCr
reference values, as recently published by our institution
[17]. These SCr reference values were obtained from chil-
dren without kidney disease, by using small age intervals
ranging from 1 day in the first week after birth up to 3
months at the end of the first year of age. Patients requir-
ing continuous HF for AKI were included in the RIFLE
category Failure. Ultimately, patients were grouped
according to the highest RIFLE score attained while
receiving ECMO. Improvement of AKI was defined as a
decline in SCr corresponding to at least one RIFLE cate-
gory. Whereas inclusion of urine output in the RIFLE
criteria has been demonstrated to be helpful to stage AKI
in critically ill patients, we decided not to use our data on
urine output. The reason for use of SCr exclusively for
determining the RIFLE category was that diuresis varied
widely, not only because of variation in kidney function,
but, more important, because of changes in clinical guide-
lines for the use of diuretic drugs over the years of the
study period [18,19].
Statistical analysis
Data were analyzed by using Statistical Package for the
Social Sciences (SPSS) version 17 for windows (SPSS,
Chicago, IL, USA). All data are expressed as median
values with interquartile range (IQR) for continuous
variables or numbers with percentages for categoric
variables, unless otherwise indicated. To obtain RIFLE
scores, SCr values were expressed in percentages of the
median of age-specific reference values. Univariate over-
all comparisons between groups (Kruskal-Wallis test or
Pearson c2 test, as appropriate) were performed to
detect differences between groups (that is, Non-AKI ver-
sus Risk versus Injury versus Failure). The Mann-Whit-
ney U test was used to compare RIFLE distributions per
ECMO day according to whether the patients survived.
Significant predictors of AKI in univariate analyses were
entered in multivariate analysis (logistic regression) to
identify independent predictors.
To evaluate the relation between AKI severity and sur-
vival until ICU discharge, a logistic regression analysis
was used to determine independent predictors for death.
Reported are odds ratios (ORs) with 95% confidence
intervals (95% CIs). The survival after ECMO decannu-
lation until ICU discharge for each RIFLE category was
additionally evaluated graphically by using a Kaplan-
Meier survival plot and log-rank tests. Two-sided P =
0.05 was considered the limit of significance in all
analyses.
Informed consent
Because of the design of this cohort study, the need for
ethics approval and informed consent was waived by the
local Medical Research & Ethics Committee of Erasmus
University Medical Center.
Results
Patients
Spanning a 14-year period from January 1992 until
January 2006, 282 neonatal patients received ECMO
support. Thirty-five patients were excluded because they
received routine HF to prevent excessive fluid accumu-
lation, despite normal pre-HF SCr levels. For three
patients, we were unable to retrieve adequate clinical
data, and two patients had congenital renal abnormal-
ities on ultrasound. Hence in total, 242 ECMO-treated
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neonates were included in the study, of whom 179 (74%)
survived to ICU discharge. Of the 63 nonsurvivors,
30 (48%) patients died within 24 hours after ECMO
decannulation, primarily because of rebound pulmonary
hypertension (Figure 1). Table 1 represents detailed
patient characteristics grouped according to the highest
RIFLE score attained during ECMO.
For all patients, the median gestational age and weight
on ICU admission was 40.0 weeks (IQR, 38.3 to 40.6)
and 3.3 kg (IQR, 2.9 to 3.7), respectively. The most
common primary diagnoses to initiate ECMO were
meconium-aspiration syndrome (MAS) (42% of all
patients) and congenital diaphragmatic hernia (CDH)
(29% of all patients). The primary diagnoses, grouped as
“other,” included failure to wean from CPB after cardiac
surgery, and concomitant respiratory syncytial virus and
Bordetella pertussis infections, mostly in children with
severe comorbidities. Median age at the start of ECMO
support was 38 hours (IQR, 26 to 63). The median
ECMO duration was 5.8 days (IQR, 3.9 to 9.4), and all
patients had been treated with venoarterial ECMO. One,
however, was initially given venovenous ECMO, but
because of insufficient circulatory support, converted to
venoarterial ECMO. Eighteen (7%) patients underwent
major surgery during ECMO, including surgical repair
of diaphragmatic hernia or congenital heart defect.
Renal function and AKI
The median number of SCr measurements while receiving
ECMO was six (IQR, four to nine) per patient. Evidence of
AKI while receiving ECMO had been documented for 153
patients (64%), with 72 in the Risk category, 55 in the
Injury category, and 26 in the Failure category (30%, 23%,
and 11% of all ECMO-treated patients, respectively). Of
the 26 patients in the Failure group, 10 (38%) received
continuous HF in addition to ECMO support for severe
metabolic derangement and fluid excess unresponsive to
diuretic therapy, as reflected by progressive edema,
ongoing oliguria, and hypertension. The median ECMO
day at which patients reached the highest RIFLE category
for the first time was day 2 (IQR, 1 to 4) for Risk, day 2
(IQR, 1 to 5) for Injury, and day 1 (IQR, 1 to 3) for Failure.
Of all 153 AKI patients, only 71 (46%) improved at least
one RIFLE category, of whom 35 (49%), 30 (42%), and six
(9%) initially were classified as Risk, Injury and Failure,
respectively. An overview of the AKI evolution is provided
in Figure 2. The median duration from the highest RIFLE
category until the start of improvement was 2 days (IQR, 1
to 5) for Risk, 2 days (IQR, 1 to 3) for Injury, and 4 days
(IQR, 3 to 6) for patients with Failure. At the end of the
study period, only 126 (52%) patients of the total pool of
242 patients were classified as Non-AKI.
In univariate analysis, patients with evidence of AKI
were younger at the start of ECMO treatment (P =
0.004). Patients who had had a cardiac arrest before
ECMO were more prone to develop AKI (P < 0.001),
whereas no correlation was found with perinatal
asphyxia or diagnosis category. The pre-ECMO use of
NO ventilation was associated with a lower incidence of
AKI (P < 0.001). Major surgery or myocardial stun dur-
ing ECMO, did not correlate with the occurrence of
AKI. Thus, variables considered for the multivariate ana-
lysis included younger age at the start of ECMO, cardiac
arrest, and NO ventilation before ECMO. By using mul-
tiple logistic regression, we found that only younger age
at the start of ECMO treatment (P = 0.004) and lack of
NO ventilation (P = 0.04) remained significant predic-
tors of AKI. Patients with AKI had a longer ECMO
duration (P = 0.012), whereas no significant increase
was noted regarding the length of ICU stay.
The survival rate in patients without AKI was 78% and
decreased to 35% in the Failure category (Table 1 and
Figure 3). Figure 4 shows the distribution of RIFLE cate-
gories on each ECMO day, according to survival. Com-
paring survivors with nonsurvivors regarding the
distributions of RIFLE categories on the different
ECMO days, we found that survivors generally had a
better (lower) RIFLE score. P values for day 1 to day 12
were significant (all P < 0.05) except for days 9, 10, and
12 (Figure 4). RIFLE was predictive for both early (<24
hours after ECMO) and late nonsurvivors (>24 hours
after ECMO) (P < 0.001), but could not discriminate
between these two outcomes (P = 0.43). Besides RIFLE
score, ECMO duration, and age at the start of ECMO
were significantly related to mortality in univariate ana-
lysis. Longer ECMO durations and younger age were
generally associated with higher mortality (both P <
0.005). Diagnostic categories also were predictive for
mortality (P < 0.001). The mortality rates for patients
diagnosed with PPHN, MAS, CDH, and the remaining
group, “other” were 4%, 5%, 63%, and 30%, respectively.
Simultaneous evaluation by using multiple logistic
regression showed that RIFLE score (P = 0.003), diag-
nostic category (P < 0.001), and ECMO duration (P <
0.001) were all independently related to mortality, whereas
no significant effect of age remained. Survival until ICU
discharge was significantly lower among Failure patients.
As a result, the adjusted odds ratio of mortality for Failure
in comparison with the other RIFLE categories combined
was 12.7 (95% CI, 3.3 to 49.5; P < 0.001). No significant
differences in survival were found between Non-AKI and
the RIFLE categories Risk and Injury (P = 0.58).
Discussion
To our knowledge, this is the first study in a large
cohort of ECMO-treated neonates evaluating the inci-
dence rate of AKI, systematically classified by the SCr-
based RIFLE criteria. On each day of ECMO treatment,
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patients were assigned SCr-based RIFLE scores by using
the actual SCr values in relation to the median of locally
collected age-specific SCr reference values, as recently
published by our institution [17]. These reference values
allowed us to identify patients reliably as having various
degrees of AKI, despite the considerable changes in SCr
due to the influence of maternal SCr and the rapidly
changing renal function throughout the first weeks of
Figure 1 Patient inclusion flowchart. Flowchart detailing inclusion and exclusion criteria for patients treated with extracorporeal membrane
oxygenation (ECMO) that resulted in the final study cohort. n, number of ECMO patients; AKI, acute kidney injury; ECMO, extracorporeal
membrane oxygenation; 24h, 24 hours.
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life, even irrespective of ECMO treatment. Furthermore,
to collect a homogeneous study group, we excluded
patients who were prophylactically treated with HF dur-
ing ECMO for fluid management as part of standard
clinical care. Moreover, we excluded patients with con-
genital renal malformations.
The incidence of AKI was 63% for the RIFLE scores
Risk, Injury, and Failure; and 34% when exclusively eval-
uating the categories Injury and Failure. These results
differ from those of other studies focusing on ECMO-
treated patients [12,14].
One study reported, in a very large cohort of approxi-
mately 10,000 ECMO patients, a much lower AKI inci-
dence rate, varying from 8.0% in neonatal patients to
20.5% in pediatric patients [14]. This discrepancy can be
explained as follows. First, data were retrieved from the
ELSO Registry database, which traditionally collects cross-
sectional information, with the possibility that the AKI
episode has been missed. Second, AKI was defined by
using the renal complication code, as stated in the ELSO
Registry (SCr >1.5 mg/dl). Although in newborns, this cut-
off value may include lower grades of AKI, in older infants,
this definition corresponds only to severe cases of the
RIFLE category Failure. Finally, 27% of all patients received
RRT according to hospital practice, of which further data
on indication, timing, and dose are not provided. Standard
HF may have prevented many patients from ever develop-
ing AKI, defined as SCr levels >1.5 mg/dl.
Table 1 Patient characteristics grouped according to the highest RIFLE score attained
RIFLE classification
Non-AKI Risk Injury Failure
n = 89 (36%) n = 72 (30%) n = 55 (23%) n = 26 (11%)
Median Median Median Median
(IQR) (IQR) (IQR) (IQR) P value*
Birth weight (kilograms) 3.3 (2.9-3.7) 3.4 (3.0-3.7) 3.3 (2.9-3.7) 3.0 (2.5-3.6) 0.242a
Apgar score
1 minute after birth 6 (3-8) 5 (3-7) 5 (3-7) 4 (1-7) 0.616a
5 minutes after birth 7 (5-9) 7 (5-8) 7 (5-8) 6 (5-8) 0.815a
10 minutes after birth 7 (6-8) 7 (6-8) 7 (4-8) 7 (6-8) 0.904a
Age at start of ECMO (hours) 44 (27-104) 36 (21-45) 38 (26-59) 38 (28-64) 0.004a
ECMO duration (days) 4.9 (3.6-8.2) 6.4 (4.2-10.2) 5.7 (4.4-8.9) 7.8 (4.5-15.1) 0.012a
Length of ICU stay (days) 8 (6-8.2) 11 (7-20.8) 10 (6-18) 14.5 (5.8-22.3) 0.178a
n (%) n (%) n (%) n (%) P value
Sex, female 41 (46%) 30 (42%) 25 (45%) 15 (58%) 0.576b
Diagnosis 0.155b
Meconium-aspiration syndrome^ 40 (45%) 35 (49%) 22 (40%) 6 (23%)
Congenital diaphragmatic hernia^ 22 (25%) 22 (30%) 13 (24%) 13 (50%)
Isolated PPHN 9 (10%) 8 (11%) 6 (11%) 3 (12%)
Other 18 (20%) 7 (10%) 14 (25%) 4 (15%)
Before ECMO
Vasopressor drugs 81 (91%) 70 (97%) 50 (91%) 24 (92%) 0.535b
Nitric oxide ventilation 80 (90%) 53 (74%) 27 (49%) 14 (54%) <0.001b
Perinatal asphyxia 48 (54%) 40 (56%) 39 (71%) 14 (54%) 0.142b
Cardiac arrest 5 (6%) 5 (7%) 14 (26%) 7 (27%) <0.001b
During ECMO
Major surgery 4 (4%) 4 (6%) 8 (15%) 2 (8%) 0.137b
Myocardial stunning 3 (3%) 4 (6%) 0 (0%) 1 (4%) 0.385b
Nonsurvivors 20 (22%) 13 (18%) 13 (24%) 17 (65%) <0.001b
Early nonsurvivors 9 (45%) 4 (31%) 8 (62%) 9 (53%)
<24 hours after ECMO
Late nonsurvivors 11 (55%) 9 (69%) 5 (38%) 8 (47%)
≥24 hours after ECMO
RIFLE categories Risk, Injury, and Failure were defined as SCr above 150%, 200%, and 300%, respectively, of the median of age-specific SCr reference values.
Continuous data are expressed as median (interquartile range (IQR)), and categoric data are expressed as number (%). AKI, acute kidney injury; ECMO,
extracorporeal membrane oxygenation; ICU, intensive care unit; IQR, interquartile range; PPHN, persistent pulmonary hypertension; RIFLE, Risk, Injury, Failure, Loss,
End-stage renal disease; SCr, serum creatinine. P values indicate overall comparison of all groups (that is, Non-AKI versus Risk versus Injury versus Failure).
Intergroup differences were assessed by using either athe Kruskal-Wallis test or bthe Pearson c2 test, as appropriate. ^Majority of the patients had severe PPHN.
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Figure 2 Evolution of acute kidney injury during extracorporeal membrane oxygenation (ECMO). Flow diagram showing the evolution of
acute kidney injury (AKI) during treatment with ECMO. After the start of ECMO, all patients were stratified according to the highest RIFLE score
attained. RIFLE categories Risk, Injury, and Failure were defined as, respectively, SCr above 150%, 200%, and 300%, of the median of age-specific
SCr reference values. Subsequently the AKI evolution over time was evaluated by using the last RIFLE score before the cessation of ECMO or on
ECMO day 12. All arrows indicate the direction of AKI evolution. Of all 153 AKI patients, only 71 (46%) patients improved at least one RIFLE
category. n, number of ECMO patients (%); AKI, acute kidney injury; NS, nonsurvivor; RIFLE, Risk, Injury, Failure, Loss, End-stage renal disease; SCr,
serum creatinine; S, survivor.
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A study by Smith and colleagues [20] demonstrated a
higher incidence of 71.7% of acute renal failure in 45
pediatric cardiac patients requiring ECMO. AKI severity
was classified with an adapted pRIFLE score, with criteria
for fluid retention added. In this study, case selection is
certainly an important selection bias, as only the most
complicated cardiac cases received ECMO. Moreover,
the incidence rate of AKI may have been overestimated,
as the category Failure also included those patients trea-
ted with HF to reduce fluid retention and electrolyte
disturbances.
Another study, in 68 neonates with CDH requiring
ECMO, reported an AKI incidence of 70.6% [12]. The
focus on solely CDH patients, with their compromised
circulation, may explain this high incidence.
In our CDH patients, the AKI incidence was compar-
able at 69%. We identified two clinical factors associated
with AKI. The favorable effect of NO ventilation before
ECMO might suggest a protective role against AKI. One
explanation is the systemic effect of inhaled NO, which
includes modulation of the distribution of systemic blood
flow and thereby potentially of renal perfusion. However,
evidence on how changes in renal perfusion are related
to the development of AKI is contradictory [21]. Another
predictor for AKI is younger age at the start of ECMO.
Patients who were younger at the start of ECMO may
have been the sicker ones, as they were not responding
to conventional therapy earlier in life.
Overall, the severity of AKI is maximal within the first
2 days after the start of ECMO. As a consequence, we
cannot exclude pre-ECMO renal injury, as the majority
of patients were in need of vasopressor drugs. The high
SCr levels throughout the first ECMO days contrast the
expected decrease in SCr due to dilution of the patients’
blood by the extracorporeal volume. The clinical course
of AKI is even more concerning, as only 46% of all
patients initially classified as AKI show some degree of
renal recovery during ECMO. In our study, survivors
Figure 3 Kaplan-Meier survival curves stratified by RIFLE category. All patients are stratified according to the highest RIFLE score attained
during ECMO. Kaplan-Meier analysis estimates, for each RIFLE category, the rate of survival until intensive care unit (ICU) discharge among all
patients after the cessation of ECMO. RIFLE categories Risk, Injury, and Failure were defined as, respectively, SCr above 150%, 200%, and 300%, of
the median of age-specific SCr reference values. The differences between the Failure category and each of the other RIFLE categories are
significant (all P < 0.001; Log-Rank test). No significant differences were found between the Non-AKI, Risk, and Injury categories. ECMO,
extracorporeal membrane oxygenation; ICU, intensive care unit; RIFLE, Risk, Injury, Failure, Loss, End-stage renal disease; SCr, serum creatinine.
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generally had a better RIFLE score than nonsurvivors.
This is in agreement with a higher survival rate (78%) in
patients without AKI compared with 35% in those with
kidney failure. The adjusted odds ratio of mortality for
Failure in comparison with the other RIFLE categories
combined was 12.7 (95% CI, 3.3 to 49.5; P < 0.001). This
high mortality risk confirms the previously reported asso-
ciation between AKI and mortality [6,11-14,20,22], and
supports the idea that patients may benefit from early
recognition of AKI and prevention of deterioration of
renal function. With the high incidence of AKI in the
present study, we should start worrying that many of
these children could develop chronic kidney disease
(CKD) in the long run [23-25].
Several limitations of this study should be addressed.
First, SCr level is a delayed measure of decreased kidney
function after AKI and is not very sensitive. Reference
values vary widely during the first days of life, in parti-
cular with the risk of overestimation of AKI. Conversely,
the ECMO circuit in neonates doubles the circulating
volume, thereby diluting SCr levels. Hence, with SCr,
the true incidence of AKI during the first days of
ECMO treatment is hard to establish. A second limita-
tion of our study is that we were not able to use urine
output for grading AKI severity, which may have
resulted in different incidences of Risk, Injury, and
Failure.
The expected first sign of AKI associated with circula-
tory failure in ECMO candidates, tubular damage due to
ischemia, may be detected early by the use of biomar-
kers in the urine, which are not affected by age or renal
maturation, increased circulating volume, or the ECMO
circuit itself. These biomarkers may prove to be more
sensitive, to enable the early diagnosis of AKI, and may
distinguish between potential AKI causes [26-29].
Conclusions
This study shows that the incidence of AKI in a large
population of ECMO-treated neonates is remarkably
high and that the severity of AKI is associated with
mortality. Because AKI during childhood may predis-
pose for CKD in adulthood, long-term follow-up of kid-
ney function after ECMO is recommended.
Key messages
Two thirds of ECMO-treated patients had AKI.
The higher the severity of AKI, the higher the risk of
death while being treated with ECMO.
Long-term monitoring of kidney function after
ECMO treatment is recommended to screen for
CKD.
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